Cooper, Demetrius v. Dombeck, Charles

CourtDistrict Court, W.D. Wisconsin
DecidedMarch 21, 2025
Docket3:23-cv-00771
StatusUnknown

This text of Cooper, Demetrius v. Dombeck, Charles (Cooper, Demetrius v. Dombeck, Charles) is published on Counsel Stack Legal Research, covering District Court, W.D. Wisconsin primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cooper, Demetrius v. Dombeck, Charles, (W.D. Wis. 2025).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF WISCONSIN

DEMETRIUS COOPER,

Plaintiff, OPINION and ORDER v.

23-cv-771-jdp CHARLES J. DOMBECK,

Defendant.

Plaintiff Demetrius Cooper, proceeding without counsel, is an inmate at Waupun Correctional Institution. Cooper alleges that defendant Charles J. Dombeck, an advance practice nurse prescriber with the Wisconsin Department of Corrections, discontinued Cooper’s prescription for pregabalin and failed to provide alternative pain medication for his chronic fibromyalgia and nerve pain. Cooper proceeds on Eighth Amendment medical care and Wisconsin-law medical negligence claims. Dombeck moves for summary judgment. Dkt. 33. The evidence shows that Dombeck conducted a diligent investigation of Cooper’s medical history, treatment, and symptoms, including consulting with DOC physicians. All his decisions were based on his medical judgment. No reasonable juror could conclude, based on the totality of Dombeck’s care, that he consciously disregarded any of Cooper’s medical conditions. I will grant Dombeck’s summary judgment motion and dismiss the case. I will deny Cooper’s motion to strike certain summary judgment submissions from Dombeck because they comply with the court’s summary judgment procedures, and I will deny Cooper’s trial-related motions as moot. Dkt. 63; Dkt. 66; Dkt. 67; Dkt. 69. UNDISPUTED FACTS The following facts are undisputed excepted where noted. Cooper has been in Department of Corrections custody since 2012. Dombeck has

worked as an advanced practice nurse prescriber (APNP) for the DOC since 2021. Cooper’s medical diagnoses that are material to this lawsuit are fibromyalgia and inguinal nerve pain (i.e., nerve pain in the groin between the lower part of the abdomen and thighs). Chronic widespread pain throughout the body may be a symptom of fibromyalgia. Cooper’s interactions with Dombeck began only in 2022, when he transferred to Waupun Correction Institution. But his prior medical history is relevant to Dombeck’s decisions. A. Care before transfer to Waupun Correctional Institution

In November 2020, Cooper received a pelvic ultrasound that revealed a left inguinal hernia. The next day, Cooper was seen by nondefendant APNP Meggan Baudek at Gundersen Rheumatology for a possible diagnosis of fibromyalgia. Cooper reported muscle and joint pain over his entire body, a family history of fibromyalgia, and that Tylenol and ibuprofen provided no relief. Baudek diagnosed Cooper with fibromyalgia and prescribed gabapentin. Dkt. 36-1 at 297–98. In early December 2020, Cooper had surgery to repair the inguinal hernia. A week later, nondefendant Dr. Amber Crawford at Gundersen General Surgery saw Cooper, who

complained of nerve pain at the incision site that extended to his scrotum and hip. Crawford said that gabapentin could help the nerve pain that he described. About a week later, nondefendant Dr. Michael Gross started Cooper on gabapentin as an urgent non-formulary request based on Crawford’s recommendation. Advanced care providers, physicians and APNPs, use the DOC’s formulary when writing prescriptions for prisoners. The providers must request approval of non-formulary drugs from the medical director, associate medical director, or psychiatry director. In late December 2020, Gross saw Cooper, who complained of fibromyalgia pain and

nerve pain in his groin area. Gross noted that the nerve pain was likely ilioinguinal nerve disruption. The same day, nondefendant Associate Medical Director Gina Buono approved Gross’s request for gabapentin. In April 2021, nondefendant APNP Jeanie Kramer saw Cooper for a hunger strike assessment. Cooper previously complained that gabapentin wasn’t stopping his pain, so Kramer suggested a trial of pregabalin. Cooper declined the pregabalin and accepted an increased dose of gabapentin. In February 2022, nondefendant Dr. Justin Boge saw Cooper at Gundersen

Neuroscience for continued complaints of inguinal pain. Boge recommended diclofenac as a conservative measure and a trial of Lyrica (a brand name for pregabalin) as an alternative to gabapentin. Dkt. 36-1 at 281–82. In late July 2022, nondefendant Dr. Shirley Godiwalla noted that gabapentin was not helpful for Cooper’s fibromyalgia and requested pregabalin as a non-formulary medication. Dkt. 36-1 at 58. Buono approved the request. Id. at 166–67. B. Care after transfer to Waupun Correctional Institution

Cooper was transferred to Waupun Correctional Institution (WCI) on August 29, 2022. Cooper didn’t receive his pregabalin upon his transfer to WCI. Cooper had another assigned provider at the time, but Dombeck was assigned to review his chart to see what medical orders should be continued from his old institution. Dkt. 36 ¶¶ 53, 135. (Cooper purports to dispute this fact, but the evidence he cites does not raise a genuine dispute. See Dkt. 51 ¶¶ 56–59.) Dombeck reviewed Cooper’s chart August 31, 2022. Dkt. 36-1 at 105. Dombeck ordered a lab test to determine whether the level of pregabalin in Cooper’s system was

therapeutic. Id. at 141. Cooper’s result was 2.3 ug/mL. Id. at 164. Dombeck says that result “essentially just show[ed] that the medication was in [Cooper’s] system.” Dkt. 36 ¶ 122. Cooper says that the result showed that his medication was “therapeutically working as prescribed.” See Dkt. 51 ¶ 90. Dombeck reviewed Cooper’s medical file going back to approximately 2019, around which time the DOC was transitioning from paper files to an electronic medical records system. See Dkt. 62 ¶ 49. (Cooper says Dombeck reviewed earlier paper files too, but this statement is immaterial.) Dombeck says that he “noted that [Cooper’s] diagnoses of fibromyalgia and

inguinal nerve pain were non-objective diagnoses, meaning they were made based on subjective reports from [Cooper] as opposed to objective clinical findings.” Dkt. 36 ¶ 59. Cooper disagrees, noting that three outside specialists diagnosed him with those conditions. Dkt. 51 ¶ 31. Cooper doesn’t directly dispute Dombeck’s statement that his medical file lacked physical signs of pain such as changes in vital signs, sweating, grimacing, flinching, moaning, guarding, or distraction by pain. See Dkt. 62 ¶¶ 56–57; see also Dkt. 36-1 at 136, 139–140, 173–200, 223, 259, 287. Nor does Cooper directly dispute Dombeck’s statement that he would expect to see these signs if a patient were in enough pain to be prescribed with pregabalin. See Dkt. 62

¶ 57. On August 31, 2022, Cooper submitted a health services request declaring that he was on a hunger and liquid strike. Dkt. 36-1 at 306. Two days later, Cooper submitted a health services request in which he said that he was on a hunger and liquid strike to protest a violation of DAI Policy 300.00.57, which relates to hunger strikes. Id. at 305. That day, Dombeck emailed nondefendant Dr. Laura Sukowaty and asked her to clarify Cooper’s pregabalin order. Dkt. 36-1 at 105. Dombeck noted that some requests had been

denied, but that pregabalin was later approved by Buono. Id. Four days later, Dombeck emailed Sukowaty and said that he would discontinue the gabapentin prescription unless Sukowaty objected. Id. at 104. Dombeck wrote that: (1) Cooper hadn’t taken adequate trials of “usual medications for chronic pain treatment”; (2) there was no objective evidence to support his subjective complaints of pain; and (3) his chart showed that he had been consistently functional even though his chart said that the gabapentin was ineffective. Id. Sukowaty agreed with Dombeck’s decision. Id. Dombeck says that an adequate medication trial requires the patient to take the

medication as prescribed from 4 to 12 weeks. Dkt. 36 ¶ 91. Cooper disagrees, but he doesn’t directly dispute that he failed to complete a 4-to-12 week trial of other pain medications. See Dkt.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
Berry v. Peterman
604 F.3d 435 (Seventh Circuit, 2010)
Forbes v. Edgar
112 F.3d 262 (Seventh Circuit, 1997)
Farmer v. Brennan
511 U.S. 825 (Supreme Court, 1994)
Carlisle v. Deere & Co.
576 F.3d 649 (Seventh Circuit, 2009)
Christopher Pyles v. Magid Fahim
771 F.3d 403 (Seventh Circuit, 2014)
Tyrone Petties v. Imhotep Carter
836 F.3d 722 (Seventh Circuit, 2016)
Roy Mitchell, Jr. v. Kevin Kallas
895 F.3d 492 (Seventh Circuit, 2018)
Lavertis Stewart v. Wexford Health Sources, Inc.
14 F.4th 757 (Seventh Circuit, 2021)
Cesal v. Moats
851 F.3d 714 (Seventh Circuit, 2017)
Wilson v. Adams
901 F.3d 816 (Seventh Circuit, 2018)
Angela Flowers v. Kia Motors Finance
105 F.4th 939 (Seventh Circuit, 2024)

Cite This Page — Counsel Stack

Bluebook (online)
Cooper, Demetrius v. Dombeck, Charles, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cooper-demetrius-v-dombeck-charles-wiwd-2025.